Improvement of exertional dyspneoa in patients with chronic obstructive pulmonary disease and severe allergic asthma responding to omalizumab

Sophie Pereira¹, Juliette Verhille¹, Emeline Cailliau², Philippe Bonniaud^{3

4}, Gilles Devouassoux^{4

5}, Stéphanie Fry^{4

6}, Laurent Guilleminault^{4

7}, Naji Khayath^{4

8}, Christophe Leroyer⁹, Cécile Chenivesse^{4

6}, Nathalie Bautin⁶

Affiliations

¹ Univ. Lille, Service de Pneumologie Immunologie Allergologie, Lille, France.
² CHU Lille, Biostatistics Department, Lille, France.
³ Department of Pulmonary Medicine and Intensive Care Unit, Dijon-Bourgogne University Hospital, Inserm U1231, Constitutive Reference Center for Rare Pulmonary Diseases, University of Bourgogne-Franche Comté, Dijon, France.
⁴ CRISALIS, F-CRIN Network, INSERM US015, Toulouse, France.
⁵ Department of Respiratory Diseases, CIERA, HCL, University Claude Bernard Lyon 1, Lyon, France.
⁶ Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019 - UMR 9017 - CIIL - Center for Infection and Immunity of Lille, Lille, France.
⁷ Department of respiratory medicine, Toulouse University Hospital, Faculty of Medicine, Toulouse, France. Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), INSERM UMR1291, CNRS UMR5051, University Toulouse III, Toulouse, France.
⁸ Chest Diseases Department, Strasbourg University Hospital, Strasbourg, France.
⁹ CIC INSERM 1412, Université de Bretagne Occidentale, Brest, France.

Sophie Pereira et al. Clin Exp Allergy. 2023 Dec.

. 2023 Dec;53(12):1298-1301.

doi: 10.1111/cea.14392. Epub 2023 Sep 13.

¹ Univ. Lille, Service de Pneumologie Immunologie Allergologie, Lille, France.
² CHU Lille, Biostatistics Department, Lille, France.
³ Department of Pulmonary Medicine and Intensive Care Unit, Dijon-Bourgogne University Hospital, Inserm U1231, Constitutive Reference Center for Rare Pulmonary Diseases, University of Bourgogne-Franche Comté, Dijon, France.
⁴ CRISALIS, F-CRIN Network, INSERM US015, Toulouse, France.
⁵ Department of Respiratory Diseases, CIERA, HCL, University Claude Bernard Lyon 1, Lyon, France.
⁶ Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019 - UMR 9017 - CIIL - Center for Infection and Immunity of Lille, Lille, France.
⁷ Department of respiratory medicine, Toulouse University Hospital, Faculty of Medicine, Toulouse, France. Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), INSERM UMR1291, CNRS UMR5051, University Toulouse III, Toulouse, France.
⁸ Chest Diseases Department, Strasbourg University Hospital, Strasbourg, France.
⁹ CIC INSERM 1412, Université de Bretagne Occidentale, Brest, France.

No abstract available

References

1. Mekov E, Nuñez A, Sin DD, et al. Update on asthma-COPD overlap (ACO): a narrative review. Int J Chron Obstruct Pulmon Dis. 2021;16:1783-1799.
1. de Oliveira JM, Cerci A, Soares FMC, Pitta F, Furlanetto KC. Adults with asthma treated with add-on omalizumab report less limitation in activities of daily living. J Bras Pneumol. 2022;48(1):e20210321.
1. Schäper C, Gläser S, Felix SB, et al. Omalizumab treatment and exercise capacity in severe asthmatics - results from a pilot study. Respir Med. 2011;105(1):3-7.
1. Maltby S, Gibson PG, Powell H, McDonald VM. Omalizumab treatment response in a population with severe allergic asthma and overlapping COPD. Chest. 2017;151(1):78-89.
1. Hanania NA, Chipps BE, Griffin NM, Yoo B, Iqbal A, Casale TB. Omalizumab effectiveness in asthma-COPD overlap: post hoc analysis of PROSPERO. J Allergy Clin Immunol. 2019;143(4):1629-1633.e2.